Marion T. Weigel

1.4k total citations
27 papers, 1.1k citations indexed

About

Marion T. Weigel is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Marion T. Weigel has authored 27 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 9 papers in Hematology and 8 papers in Oncology. Recurrent topics in Marion T. Weigel's work include Chronic Myeloid Leukemia Treatments (9 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Ovarian cancer diagnosis and treatment (6 papers). Marion T. Weigel is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Ovarian cancer diagnosis and treatment (6 papers). Marion T. Weigel collaborates with scholars based in Germany, United Kingdom and United States. Marion T. Weigel's co-authors include Mitch Dowsett, W. Jonat, Christoph Mundhenke, İbrahim Alkatout, Nicolaì Maass, Christian Schem, Dirk Bauerschlag, Lesley‐Ann Martin, Melanie Schubert and Veronika Günther and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Marion T. Weigel

27 papers receiving 1.0k citations

Peers

Marion T. Weigel
Paul J. van Diest Netherlands
Shane R. Stecklein United States
Lin Guo China
Neda A. Moatamed United States
Ann‐Marie Baker United Kingdom
Richard Hutson United Kingdom
Paul J. van Diest Netherlands
Marion T. Weigel
Citations per year, relative to Marion T. Weigel Marion T. Weigel (= 1×) peers Paul J. van Diest

Countries citing papers authored by Marion T. Weigel

Since Specialization
Citations

This map shows the geographic impact of Marion T. Weigel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marion T. Weigel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marion T. Weigel more than expected).

Fields of papers citing papers by Marion T. Weigel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marion T. Weigel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marion T. Weigel. The network helps show where Marion T. Weigel may publish in the future.

Co-authorship network of co-authors of Marion T. Weigel

This figure shows the co-authorship network connecting the top 25 collaborators of Marion T. Weigel. A scholar is included among the top collaborators of Marion T. Weigel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marion T. Weigel. Marion T. Weigel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mabrouk, Mohamed, et al.. (2021). Evaluation of Laparoscopy Virtual Reality Training on the Improvement of Trainees’ Surgical Skills. Medicina. 57(2). 130–130. 10 indexed citations
2.
Alkatout, İbrahim, Veronika Günther, Melanie Schubert, et al.. (2015). Vulvar cancer: epidemiology, clinical presentation, and management options. International Journal of Women s Health. 7. 305–305. 140 indexed citations
3.
Weigel, Marion T., İbrahim Alkatout, Antonia Wenners, et al.. (2014). Nilotinib in Combination with Carboplatin and Paclitaxel Is a Candidate for Ovarian Cancer Treatment. Oncology. 87(4). 232–245. 14 indexed citations
4.
Maass, Nicolaì, Christian Schem, Dirk Bauerschlag, et al.. (2014). Final Safety and Efficacy Analysis of a Phase I/II Trial with Imatinib and Vinorelbine for Patients with Metastatic Breast Cancer. Oncology. 87(5). 300–310. 12 indexed citations
5.
Schollmeyer, Thoralf, İbrahim Alkatout, Ivo Meinhold‐Heerlein, et al.. (2014). Hysterectomy trends over a 9‐year period in an endoscopic teaching center. International Journal of Gynecology & Obstetrics. 126(1). 45–49. 19 indexed citations
6.
Tiemann, Katharina, Marion T. Weigel, İbrahim Alkatout, et al.. (2014). Significance of syndecan-1 expression in ductal carcinoma in situ of the breast.. PubMed. 34(7). 3607–16. 11 indexed citations
7.
Weigel, Marion T., Zara Ghazoui, Anita K. Dunbier, et al.. (2012). Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Research. 14(3). R78–R78. 38 indexed citations
8.
Weigel, Marion T., Susana Banerjee, Mónica Arnedos, et al.. (2012). Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Annals of Oncology. 24(1). 126–133. 36 indexed citations
9.
Weigel, Marion T., Julia Krämer, Christian Schem, et al.. (2011). Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma. European Journal of Obstetrics & Gynecology and Reproductive Biology. 160(1). 74–78. 50 indexed citations
10.
Bauerschlag, Dirk, Ole Ammerpohl, Karen Bräutigam, et al.. (2011). Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation Profiles. Oncology. 80(1-2). 12–20. 39 indexed citations
11.
Martin, Lesley‐Ann, Zara Ghazoui, Marion T. Weigel, et al.. (2011). An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition. Steroids. 76(8). 772–776. 17 indexed citations
12.
Martin, Lesley‐Ann, Giles Davies, Marion T. Weigel, et al.. (2010). Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Research and Treatment. 123(3). 829–836. 34 indexed citations
13.
Weigel, Marion T. & Mitch Dowsett. (2010). Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocrine Related Cancer. 17(4). R245–R262. 382 indexed citations
14.
Weigel, Marion T., Christian Schem, Dirk Bauerschlag, et al.. (2010). In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. BMC Cancer. 10(1). 412–412. 51 indexed citations
15.
Bräutigam, Karen, Dirk Bauerschlag, Marion T. Weigel, et al.. (2009). Combination of Enzastaurin and Pemetrexed Inhibits Cell Growth and Induces Apoptosis of Chemoresistant Ovarian Cancer Cells Regulating Extracellular Signal-Regulated Kinase 1/2 Phosphorylation. Translational Oncology. 2(3). 164–IN1. 15 indexed citations
16.
Bauerschlag, Dirk, Christian Schem, Marion T. Weigel, et al.. (2009). The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer. Journal of Cancer Research and Clinical Oncology. 136(1). 79–88. 7 indexed citations
17.
Schem, Christian, Marion T. Weigel, Alexander Strauß, et al.. (2009). Leiomyomatosis peritonealis disseminata in a pregnant woman. Archives of Gynecology and Obstetrics. 281(1). 123–127. 6 indexed citations
18.
Mundhenke, Christoph, Marion T. Weigel, Klarissa Hanja Stürner, et al.. (2008). Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. Journal of Cancer Research and Clinical Oncology. 134(12). 1397–1405. 24 indexed citations
19.
Bolling, Claus, Feliksas Jankevičius, Alvydas Česas, et al.. (2006). Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Investigational New Drugs. 24(6). 521–527. 58 indexed citations
20.
Lang, Johannes & Marion T. Weigel. (1983). Nerve-vessel relations in the region of the jugular foramen. Surgical and Radiologic Anatomy. 5(1). 41–56. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026